host in Medical Technology

Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS

... Make Synaptic Contact with host Motor Neurons ROCKVILLE, Md., March 9 ... therapy is that the cells can integrate into the host to provide function in addition to providing ... receiving live-cell grafts, a large number of host motor neurons had been contacted by human neurons ...

BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB

... hands in our individual efforts to help host nations develop robust laboratory facilities, we ... companies like BD and working in partnership with host nations, we will achieve more in the fight ... integrate laboratory and health systems in our host countries." "Our experience in sub-Saharan ...

Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles

... 2007, Artists for a New South Africa (ANSA) will host "Shaking The Blues," a star-studded benefit, at ... and Keisha Nash-Whitaker & Forest Whitaker. host committee members include J.J. Abrams, ... luminaries. "Last year, ANSA was honored to host the 75th birthday celebration for our dear friend ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... the earlier TASKi trials and appear to be manageable. Rigel will host a conference call today at 7PM EDT/ 4PM PDT to discuss these results (see ... Conference Call and Webcast Information Rigel will host a conference call to discuss the R788 TASKi3 Phase 2b clinical trial of ...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

... RA in the first half of 2010 with a corporate partner. Rigel will host a conference call today at 8:00am EDT/5:00am PDT to discuss these results ... disease. Conference Call and Webcast Information Rigel will host a conference call to discuss the R788 TASKi2 Phase 2b clinical trial of ...

Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction

... Management will host Conference Call at 9:00 AM ET Today CORAL GABLES, Fla., May 29 ... as they are developed." Conference Call The Company will host a conference call today at 9:00 AM ET to discuss the trial results. ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... Treatment of Colorectal Cancer - - Poniard Management Team to host Analyst and Investor Briefing to Discuss Data on Sunday, May 31st - ... colorectal cancer." Analyst and Investor Briefing Poniard will host an investor event in Orlando on Sunday, May 31, 2009. Presentations will ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... Cellular Immunotherapy for Cancer to Prolong Survival - - Company to host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 ... Conference Call Scheduled for Today at 5:30 pm ET Dendreon will host a conference call today at 5:30 pm ET. To access the live call, dial ...

Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication

... adrenergic system, the body's control center for regulating stress and a host of other physiologic functions. The Durham-based specialty pharmaceutical ... with ADHD. Adrenergic dysregulation also may play a major role in a host of adult conditions such as post-traumatic stress syndrome, menopausal ...

Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain

... ENDPOINTS; MIXED RESULTS IN EXPLORATORY ENDPOINTS COMPANY TO host CONFERENCE CALL AND WEBCAST THURSDAY, MARCH 26TH AT 8:00AM ET / 5:00AM ... Conference Call and Webcast Information The Company will host a live conference call and webcast to provide additional details of this ...

Savient Provides Update on Pegloticase BLA

... FDA Extends PDUFA Action Date to July 30, 2009 Company to host Conference Call EAST BRUNSWICK, N.J., Feb. 12 ... Agency (EMEA). Company Hosts Conference Call The Company will host a conference call and webcast today, Thursday, February 12, 2009 at 7:00 ...

Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations

... cell based product, is under development to prevent acute Graft versus host Disease (GvHD) and allow early immune reconstitution following ... this would not be possible because of the high risk of acute Graft versus host Disease with mismatched donor immune cells. This is obviously a very ...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

... of the microorganism and because of the paradoxical immune response of the host animal to infection. During the early sub clinical stages of infection, ... presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, ...

SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results

... for the three and nine months ended September 30, 2008. The Company will host a live conference call today, November 7, 2008, at 11:30 a.m. (Eastern ... securities. Conference Call As previously announced, SCOLR Pharma will host a conference call on November 7, 2008, at 11:30 a.m. (Eastern Standard ...

Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis

... Secondary Efficacy Endpoints Company to host Conference Call and Webcast Wednesday, September 3rd at ... trial. Conference Call and Webcast Information The Company will host a live conference call and webcast to provide additional details of this ...

Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test

... Achieved Based on Compelling Clinical Studies - Company to host Roundtable Conference Call on July 15 FREMONT, Calif., June 25 ... of women who could benefit considerably from the test." Vermillion will host a roundtable teleconference to address the need for OVA1 on Tuesday, July ...

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

... on Malignant Lymphoma in Lugano, Switzerland later this week. Rigel will host a conference call today at 8:00 a.m. EDT to discuss these results (see ... of the disease is common. Conference Call Information Rigel will host a conference call to discuss the lymphoma results today, June 3, 2008, at ...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

... - Company to host Conference Call/Webcast at 8:30 a.m. EDT on May 29 - SOMERSET, N.J., May ... European Union and Australia. Conference Call & Webcast Alfacell will host a conference call and Webcast to discuss the preliminary results at 8:30 ....

Prostate Cancer Treatment Offers Results Without Side Effects

... cause impotence (erectile dysfunction), incontinence (urine leakage) or a host of other side effects. He went on a raw food diet, had his dental amalgams ... incontinent. Since virtually all treatments offered in the USA come with a host of undesirable side effects, many patients like Mike Strong are seeking ...

XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting

... Company Will host Webcast to Review Data Tuesday, May 13 at 1:00 p.m. EDT ... III Webcast and Slide Presentation As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM III data ...

Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454

... -Memory Receives $6 Million Milestone Payment- -Memory to host Conference Call at 9:00 a.m. EDT Today- MONTVALE, N.J. and BASEL, ... of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the ...

Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint

... Company to host a conference call Monday, March 10, 2008 at 8:30am NEW YORK, March 7 ... high-dose Phase 2 trial before the end of the year." The Company will host a conference call on Monday, March 10, 2008 at 8:30am ET. In order to ...

TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

... Streamlining of Operations - - Company to host Conference Call/Webcast at 11 a.m. EST Today - LA JOLLA, Calif., Feb. 14 ... Conference Call/Webcast Information TorreyPines Therapeutics will host a conference call and Webcast at 11 a.m. EST today. The audio Webcast can ...

Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study

... to the currently marketed biological agents. Rigel will host a conference call today at 12:30 p.m. EST to discuss these results (see ... the progression of the disease. Conference Call Information Rigel will host a conference call to discuss the R788 Phase 2 clinical trial results ...

Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology

... Center in Atlanta, Georgia. On December 10, 2007, Sunesis management will host a conference call for investors to discuss the data being presented. ... a.m. to 7:00 p.m. Conference Call Information Sunesis management will host a conference call to discuss data being presented at the ASH meeting on ...

XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System

... Stent Thrombosis - Company Also Provides Clinical Program Update and Will host Webcast Mon., Oct. 22 at 7:00 a.m. ET - ... and II Webcast and Slide Presentation As previously announced, XTENT will host a teleconference and slide presentation to review the CUSTOM I and CUSTOM ...

Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007

... at this time. -- Analyst Meeting. At 5:30 p.m., the Company will host an analyst meeting in the Grand Ballroom of the Renaissance Hotel. ... on Drug-Eluting Stents. From 8:00 - 10:00 p.m., the Company will host a symposium entitled "Preclinical to Patients: The DES Pathway" ...

XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007

... Company Also to host Drug-Eluting Stent Symposium and Analyst Webcast MENLO PARK, Calif., ... Webcast and Teleconference on CUSTOM I and CUSTOM II Data XTENT will host a webcast and teleconference call to review the CUSTOM I and CUSTOM II ...

Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients

... Symposium in New York City - Isis Will host a Conference Call on Monday, October 8, at 8:00 a.m. E.T. ... in an oral session at DALM on Saturday at 3:45 p.m. E.T., and Isis will host a conference call Monday morning at 8:00 a.m. E.T. to further discuss ...

Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months

... and Continuous Abstinence by Dose, Schedule and Antibody Response; Nabi to host Conference Call Today BOCA RATON, Fla., ... 2007 in Orlando, Florida on November 7, 2007. Conference Call Nabi will host a live webcast at 5:30 p.m. EDT today, September 5, to discuss these ...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007

... Rhythm Management Workshop Session. At 12:45 p.m., the Company will host a workshop entitled "Cardiac Resynchronisation Therapy: all you need ... -- Symposium on Drug-Eluting Stents. At 2:00 p.m., the Company will host a symposium entitled "What's the evidence for using drug-eluting ...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

... Time. Details are below: Howard Robin, president and chief executive officer, and John Nicholson, chief financial officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) on Tuesday, August 4, 2009. To access the ...

Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C

... of any future combination treatment regimen for HCV." Conference Call and Webcast Members of Pharmasset's management team will host a conference call today, Friday, July 31, 2009, at 8:00 a.m. ET to discuss the preliminary results of the multiple ascending dose trial with ....

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

... markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time. Orexigen management will host the call and webcast to discuss the results of these clinical trials and answer questions. The live call may be accessed by phone by calling ...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

... SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am EDT (5:00 am PDT). Members of Rigel's senior management team and the principal investigator ...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

... even when they get identical medical treatment and other confounding socioeconomic factors are controlled for. The finding points to biological or host genetic factors as the potential source of the survival gap. "When you look at the dialogue about the issue of race and cancer survival that's ...

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

... Minn. -- Summer isn't always fun in the sun. Intense sunlight, hot and humid temperatures, poisonous plants and biting insects can cause a host of skin problems. The June issue of Mayo Clinic Women's HealthSource offers ways to prevent and treat common summer skin problems. Heat rash ...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... for infections, and appropriate actions should be taken. The possibility exists for TNF-blocking agents, including SIMPONI, to affect host defenses against infections and malignancies. Treatment with SIMPONI may result in the formation of auto-antibodies and, rarely, in the development ...

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

... Update of an ongoing Phase II study. 14th Congress of the EHA 2009, abstract no. 482 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of ...

Micromet Presents Update on Blinatumomab's Response Rate and Duration in a Phase 1 Study in Non-Hodgkin's Lymphoma Patients

... the Ongoing Phase I Study MT103-104 in Patients with Relapsed NHL. ASH 2008, abstract number 267 Webcast/Conference Call Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S. Eastern time to discuss the blinatumomab data presented at the 14th Congress of ...